Compare Inovio Pharmaceuticals Inc (INO) vs Jones Lang LaSalle Inc (JLL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Jones Lang LaSalle Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.15 (market cap $112.19M), while Jones Lang LaSalle Inc trades at $299.87 (market cap $13.95B). The key difference: Jones Lang LaSalle Inc is far larger — about 124.3× Inovio Pharmaceuticals Inc's market cap, and Jones Lang LaSalle Inc is more actively traded (457,462 versus 3,201,278). Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Jones Lang LaSalle Inc for 71 Days on average.
| INO | JLL | |
|---|---|---|
Market Cap | $112.19M | $13.95B |
Volume | 3,201,278 | 457,462 |
Sector | Health | Real Estate |
52-Week High | $2.65 | $392.79 |
52-Week Low | $0.66 | $280.16 |
Typical Hold Time | 43 Days | 71 Days |
Enterprise Value | $83.51M | $16.71B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.15, down 0.43% on the day, with a bearish technical signal from moving averages and oscillators. The company shows consistent quarterly earnings beats but operates at significant losses with a -130,000% net income margin and negative cash flow. Key catalyst is the FDA's October 30, 2026 PDUFA date for INO-3107, with analyst consensus leaning bullish at a $2.75 price target.
The investment case hinges on FDA approval of INO-3107, offering substantial upside from current levels. However, persistent cash burn, minimal revenue, and high valuation multiples relative to sales pose significant risks. Investors face binary outcomes driven by regulatory decisions and commercialization execution.
JLL trades at $299.87, up 1.08% today, with a bearish technical signal but strong fundamentals. The stock shows consistent earnings beats, with Q2 2026 EPS of $5.26 exceeding the $4.56 estimate. Revenue grew to $26.12B in 2025, and net income margin improved to 3.64%. Recent news highlights acquisitions and financing deals, such as the $406M Trammell Crow Center financing announced on September 24, 2026.
The outlook is positive, supported by analyst consensus price target of $450.50 and 58.33% buy ratings. Key opportunities include growth in data center operations and proprietary platforms, while risks involve real estate market volatility and competitive pressures. The stock offers value with a P/E of 14.54 and P/S of 0.53, but investors should monitor debt levels and economic cycles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →
